Ga-PentixaFor

Phase 2Small molecule

NNantes University Hospital

Ga-PentixaFor is one of 87 small molecule programs targeting Hyperaldosteronism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperaldosteronismRecruiting

Multiple MyelomaRecruiting

Small Cell Lung CancerNot yet recruiting

HyperaldosteronismPhase 2

Recruiting

Multiple MyelomaPhase 2

Recruiting

Small Cell Lung CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

17 2

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 3

Biaxin

AbbVie

Phase 3

15 4

Opdivo

Bristol-Myers Squibb

Phase 3

11 5

Neulasta

Amgen

Phase 3

5 6

Cytosar

Teva

Phase 3

4 7

Mozobil

GGenzyme, a Sanofi Company

Phase 3

15 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 9

Linvoseltamab

Etentamig

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ARecruiting

Multiple Myeloma

NCT06871176

Q2 2028

Phase 2Recruiting

Hyperaldosteronism

NCT06246357

Q3 2029

Phase 1Not yet recruiting

Small Cell Lung Cancer

NCT07007325

Q2 2030

Phase 2Recruiting

Multiple Myeloma

NCT04561492

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

Recruiting·NNantes University Hospital·Phase 2·NCT04561492·45 enrolled

Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.

Withdrawn·NNantes University Hospital·Phase 2·NCT05321862

PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

Recruiting·UUniversity Health Network, Toronto·N/A·NCT06871176·30 enrolled

Lymphoma1 trial

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Terminated·PPentixapharm AG·Phase 3·NCT06125028·13 enrolled

Small Cell Lung Cancer1 trial

Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis and Disease Progression

Not yet recruiting·IInstitut Cancerologie de l'Ouest·Phase 1·NCT07007325·15 enrolled

Hyperaldosteronism1 trial

Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06246357·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Ga-PentixaFor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-PentixaFor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-PentixaFor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nantes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNantes University Hospital

Ga-PentixaFor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q3 2029

Q2 2030

Trials by Indication[1]

Multiple Myeloma3 trials

Lymphoma1 trial

Small Cell Lung Cancer1 trial

Hyperaldosteronism1 trial

References

Drug Info

Quick Facts

Related News